(firstQuint)A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine.

 This is a phase I, prospective, randomized, open-label, two-center study.

 A total 60 healthy volunteers will be screened for baseline characteristic inclusion/exclusion criteria after providing a written informed consent.

 Eligible subjects will be recruited and equally randomized to either receive 2 doses of EV71 vaccine 0.

25ml or 0.

5ml.

 All subjects should be followed till Day 210.

.

 A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine@highlight

This study is aims to evaluate the safety, reactogenicity and immunogenicity of EV71 vaccine at a 0.

25ml or 0.

5ml dose in health volunteers